1 Lower levels of household transmission of SARS-CoV-2 VOC Omicron compared to Wild-type: an 2 interplay between transmissibility and immune status AMAM Winkel MD^{a #}, E Kozanli MSc^{b #}, ME Haverkort MD^c, SM Euser PhD^{a,d}, JGC Sluiter-Post MSc^a, R 3 Mariman PhD^b, A. Vogelzang^b MSc, J. de Bakker BSc^b, C.R. Lap MD^a, MA van Houten MD,PhD^{a,e}, D Eggink 4 PhD^b*, SFL van Lelyveld MD,PhD^{a,f}* 5 ^a Spaarne Gasthuis Academy, Hoofddorp, The Netherlands 6 ^b Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The 7 8 Netherlands ^c Department of Infectious Disease Control, Public Health Services Kennemerland, Haarlem, The Netherlands 9 ^d Regional Public Health Laboratory Kennemerland, Haarlem, The Netherlands 10 11 ^e Department of Paediatrics, Spaarne Gasthuis, Haarlem/Hoofddorp, The Netherlands 12 ^f Department of Internal Medicine, Spaarne Gasthuis Hospital, Haarlem/Hoofddorp, The Netherlands # shared first authors 13 14 * Corresponding authors and shared last authors: 15 D Eggink, E-mail: dirk.eggink@rivm.nl. 16 SFL van Lelyveld, E-mail: s.van.lelyveld@spaarnegasthuis.nl 17 18 Key words: SARS-CoV-2; COVID-19; household transmission; Omicron; BA.2; saliva 19 20 Manuscript word count: 3789 21 Abstract word count: 250

Abstract 22 23 Background 24 Knowledge of SARS-CoV-2 household transmission dynamics guides infection control and vaccination 25 measures. This household cohort study prospectively assessed the impact of both the Omicron BA.2 variant and 26 immunity on household transmission using dense saliva sampling and sequence analysis. 27 Methods 28 Households consisting of a PCR-confirmed index and at least two household members were enrolled in March 29 and April 2022 during the Omicron BA.2 wave in the Netherlands. SARS-CoV-2 PCR was performed on ten 30 consecutive saliva samples. Serum-antibodies were measured at baseline and day 42. Whole genome sequencing 31 was performed for phylogenetic analysis, followed by sensitivity analysis, to correct for multiple household 32 introductions and index definition. Results were compared with the identical, early-pandemic and pre-33 immunisation predecessor study. 34 Results 35 Sixty-seven households were included, consisting of 241 individuals (median age 33.0 years). Maximum 36 household Secondary Attack Rate (SAR) was 59.7%, per-person SAR 41.5%. Underage indexes were more 37 likely to transmit. Transmission was negatively affected by household members' immunity. Phylogenetic 38 analysis showed multiple introductions in four households. Sensitivity analysis resulted in a minimal household 39 SAR of 51.0% and per-person SAR of 28.5%. 40 Conclusions 41 The Omicron BA.2 variant is highly transmissible within households. Nevertheless, transmission rates are lower 42 than our pre-immunisation reported ancestral rates: household SAR decreased from 88.2% to 59.7%, per-person 43 SAR from 64.3% to 41.5%, implying immunity reduces transmission, even for a more transmittable variant. 44 Regardless of immune status, children have a crucial role in Omicron household transmission. Intensive 45 sampling and phylogenetic analysis are essential to correctly calculate transmission rate, especially in times of 46 minimal behavioural restrictions. 47

50 51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

1. Introduction Since the first identification in December 2019, severe acute respiratory syndrome coronavirus (SARS-CoV-2) has quickly spread worldwide, causing a global pandemic characterised by the continuous emergence of new variants. The SARS-CoV-2 variant B.1.1.529, referred to as the Omicron variant of concern (VOC), was first reported in November 2021 and has become the most prevalent variant globally. This variant has diversified into various Omicron sublineages, Initially, five sublineages were identified, called BA.1-BA.5.2 BA.1 was introduced in the Netherlands in November 2021 and became the dominant variant within several weeks. This sublineage was rapidly replaced by BA.2, which was dominant in the Netherlands during this study in March and April 2022, followed by the dominance of BA.5 in June 2022. The Omicron VOC sublineages BA.1-BA.5 have been reported to be more infectious than previous variants. Moreover, Omicron is less sensitive to neutralising antibodies induced by vaccine or natural infection with a previous variant.⁵ These characteristics of Omicron VOCs facilitate infections in immunized individuals – even in those who received a booster vaccination, keeping SARS-CoV-2 highly transmissible.⁶ Households are of significant importance for SARS-CoV-2 transmission due to proximity and duration of exposure. Estimated SARS-CoV-2 household transmission rates vary between 9.0% and 88.2% for different variants. 8,9 The highest per-person Secondary Attack Rates (SARs) have been reported by prospective household studies using frequent sampling. 10,11 Likewise, our initial early-pandemic prospective cohort study using frequent saliva sampling found very high household transmission rates (88.2%). However, this study was performed between October and December 2020, when the ancestral variant was still dominating (Nextclade 20A, 20B, 20E (EU1)), and the national COVID-19 vaccination program had not yet been implemented. By March 2022, 84.9% of people in the Netherlands aged 12 and over had received the primary vaccination series, and 58.1% had received a booster vaccination.¹² Furthermore, 60% of the Dutch population was estimated to have suffered a previous infection, resulting in 95% of the population having SARS-CoV-2 serum-antibodies.¹³ It is therefore highly likely that SARS-CoV-2 Omicron household transmission dynamics within an immunized population differ from the results described in the initial study and other pre-Omicron performed household studies. Prospective data regarding household transmission in the Omicron era are scarce. Most published studies extracted transmission data from register data, 14-17 or contact tracing programs, 18 This strategy misses most asymptomatic and mild cases since SARS-CoV-2 testing is mostly performed in case of respiratory symptoms. Since infection with Omicron often leads to milder symptoms than previous variants, reported transmission rates are possibly underestimated.¹⁹ In addition, phylogenetic analysis, essential for the exclusion of multiple

introductions from outside the household, is seldom performed. The net impact of the Omicron BA.2 VOC on household transmission among vaccinated and/or previous infected household members is of interest, since it could have implications for infection control and vaccination strategies.

The present study aimed to prospectively assess household transmission dynamics of Omicron BA.2 VOC and factors associated with transmission on household, index case, and household member levels using dense saliva sampling and phylogenetic analysis. The identical study design of both this and the initial study offered a unique opportunity to compare household transmission data between different pandemic phases.

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

2. Methods 2.1. Study design and participants In this prospective cohort study, largely identical to the initial early-pandemic household transmission study, households were recruited in March and April 2022, during the SARS-CoV-2 Omicron (B.1.1.529) wave in the Netherlands, when Omicron sublineage BA.2 was dominant. Index cases were recruited at the Public Health Services Kennemerland, the Netherlands, when testing for SARS-CoV-2 through reversed transcription polymerase chain reaction (RT-PCR) on a combined nasopharyngeal swab (NPS) and oropharyngeal swab (OPS). The indexes and their households were eligible if (1) the index was 65 years or younger and had a SARS-CoV-2 positive RT-PCR maximal 72 hours before study inclusion, and (2) at least two additional household members not diagnosed with SARS-CoV-2 in the previous eight weeks were willing to participate in the study. Indexes could be either symptomatic or asymptomatic. A household was considered to have two indexes if both participants tested positive for SARS-CoV-2 at the same moment and symptoms started simultaneously. For detailed case definitions see Supplementary Methods. All participants provided written informed consent. The Medical Ethical Committee of the Amsterdam University Medical Centre, The Netherlands, reviewed and approved this study (reference number 2022.0073). 2.2. Measurements Sample collection Saliva samples were obtained by self-sampling at home on days 1, 3, 5, 7, 10, 14, 21, 28, 35, and 42, with the day of inclusion as day 1. On days 1 and 42, capillary blood samples were collected by the research team during a home visit (Figure I). The sampling scheme was identical for index cases and household members. See Supplementary Materials for details. Questionnaires An online baseline questionnaire obtained on day 1 contained questions on household composition, household characteristics, medical history, previous SARS-CoV-2 infection(s), and SARS-CoV-2 vaccination status. Online symptomatology questionnaires were sent to the participants each night before the pre-defined time points for saliva collection. Recently SARS-CoV-2 positive household members (RPHM) Household members with a confirmed SARS-CoV-2 infection (by either RT-PCR or rapid antigen self-test) up to eight weeks before study onset were defined as recently SARS-CoV-2 positive household members (RPHMs).

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

2.5. Statistical methods

RPHMs were not eligible to fully participate in the study as RNA detection from the earlier infection might affect transmission data.²⁰ However, these participants could conceivably be the actual index of the household. To investigate a possible role of RPHMs in SARS-CoV-2 transmission within the household, their NP/OPsamples were requested from the Public Health Services and sequenced. Additionally, these household members completed a questionnaire regarding their recent SARS-CoV-2 infection, including test date, symptom start date, duration and severity of symptoms. 2.3. Definitions Infection of household members during study follow-up (secondary cases) was defined as SARS-CoV-2 positive RT-PCR in the saliva of at least one of the ten time points and/or a >5-fold rise of SARS-CoV-2 specific antibodies in serum between day 1 and day 42. Household transmission was expressed in the household secondary attack rate (SAR) and per-person SAR. The household SAR, defined as SARS-CoV-2 infection of at least one household member during study follow-up, was calculated by dividing households with transmission by the total number of households. The per-person SAR, defined as the risk of household members to get infected, was calculated by dividing the number of secondary cases by the number of participating household members. Participants were divided based on self-reported immunity status into naive, previous infection only, previous vaccination only and hybrid immunity (both SARS-CoV-2 vaccination and previous infection). 2.4. Molecular diagnostics and serology The methodology for molecular diagnostics and serology analysis is similar to our initial early-pandemic study and is described in detail in the Supplementary Materials. Sera of all individuals were tested for IgG-type antibodies against SARS-CoV-2 antigens. Protein microarray was used to quantify fluorescent signal of a duplicate 3-fold serial dilutions starting at 1:20. In saliva, cycle threshold (Ct)-values were determined using RT-PCR for the presence of SARS-CoV-2. Subsequently, RT-PCR-positive samples of each participant with the lowest Ct-value were sequenced in amplicon-based SARS-CoV-2 sequencing for phylogenetic analysis (see phylogenetic analysis).²¹ The SARS-CoV-2 sequences from the participants are compared through a phylogenetic analysis. A maximum likelihood phylogenetic tree is built to display clustering of sequences (Figure II). The proximity of sequences of household members distinguishes actual transmission within a household from an external introduction. Based on this analysis, we could correct for external introductions in our sensitivity analysis to calculate a minimal SAR.

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

Logistic regression was used to a) compare characteristics of households and to assess the association between household characteristics and household transmission (table II), b) compare characteristics of index cases and to assess the association between index case characteristics and transmission to its' household members (transmission probability) (table III), c) compare characteristics of household members and to assess the association between household member characteristics and secondary infection of household members (Table IV). Statistical analyses were performed with SPSS version 28.0.0.0. P-values <0.05 were considered statistically significant. Sensitivity analysis The household and per-person SARs calculated based on RT-PCR and serological results represent the maximum SAR, including every SARS-CoV-2 infection within a household during study follow-up. However, this method does not consider additional external introductions, leading to possible overestimation of transmission rates. A sensitivity analysis was performed to calculate a minimal household and per-person SAR, only taking into account transmission from index to household member(s) confirmed by phylogenetic analysis. The sensitivity analysis also accounts for the influence of the index case definition on the SAR. Our defined index cases might not have been the primary cases of the household, since RPHMs could be the actual index cases of the households, therefore distorting reported household transmission dynamics. This analysis thus corrects for 1) multiple introductions within the household as measured by whole genome sequencing and phylogenetic analysis, and 2) an RPHM being the actual index case. Then, a minimal household SAR and minimal per-person SAR were calculated. See Supplementary Methods for a detailed description of the corrections made in the sensitivity analysis.

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

3. Results

3.1. Baseline characteristics Sixty-seven households were included, comprising 241 participants, of whom 70 index cases and 171 household members (Table I). In addition, 21 RPHMs were included (Supplementary Table IV). For three households, two indexes were identified. For all participants collecting specimens (n=241), protocol adherence for collection of the specimens was 93.1% (95.9% saliva and 90.2% serum) (Supplementary Table V). Baseline characteristics of indexes and household members are shown in Table I. Most indexes were female (61.4%). Children aged <18 years accounted for 34.4% of the indexes and 44.4% of household members. Most indexes (88.6%) and household members (89.5%) had pre-existing immunity from a laboratory-confirmed SARS-CoV-2 infection, vaccination, or both. The household characteristics are presented in Table II. The median household size was 4.0 participating household members (IOR 4.0-4.0) (Table II). The median time between index symptom onset and study enrolment (day 1) was 3.0 days (IQR 2.0-4.0) (Table III). 3.2. Household SAR and associations between index characteristics and SARS-CoV-2 household transmission Secondary infection of one or more household members was detected in 40 of 67 households, leading to a household SAR of 59.7% (Table II). The median household size did not differ between households with and without transmission (4.0 [IQR 4.0–4.0] vs 4.0 [IQR 4.0–4.0]; p=0.798). Transmission was detected in most households with index cases under the age of 18 (20/24, 83.3%) (Table III). Children had higher odds of transmitting SARS-CoV-2 to household contacts compared with adult indexes. This persisted when adjusted for baseline antibody titer (univariate OR 5.46, 95% CI 1.61-18.47, p=0.006; multivariate OR 4.75, 95% CI 1.15–19.64, p=0.031; Table III). Other index-case characteristics, such as index symptom status or participant-reported pre-existing immunity status (infection and/or vaccination), were not statistically significantly associated with household transmission. Higher baseline antibody titer of the index case was associated with lower household transmission, however not statistically significant when correcting for age (univariate OR 0.95, 95% CI 0.90-1.00, p=0.049; multivariate OR 1.00, 95% CI 0.92-1.02, p=0.237).

3.3. Per-person SAR and associations between household member characteristics and SARS-CoV-2 infection

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

At the household member level, secondary infection was detected in 71 of 171 individuals, leading to a perperson SAR of 41.5% (Table IV). Most secondary cases already tested positive in saliva at day 1 (42/71, 61.8%). Secondary cases reported more symptoms than negative household members. The median age did not differ between secondary and non-secondary cases (36.0 [IQR 10.0-46.0] vs 20.0 [IQR 12.0-45.0]; p=0.620) (Table IV). Household members with self-reported hybrid immunity and with previous infection only, had significantly lower odds for secondary infection compared to naïve members (OR 0.04 [95% CI 0.01–0.17]; p <0.001) vs (OR 0.13 [95% CI 0.03–0.56]; p=0.006). Previous vaccination only did not significantly lower the odds for secondary infection, independent from the number of prior vaccinations. To analyse the association between the immune status of household members and secondary infection more specifically, members were grouped based on baseline antibody titer. Household members with high antibody titers (>3000) at day 1 had significantly lower odds for secondary infection compared to naïve members (antibody titer ≤10) (Table IV). Moreover, the median day 1 titer of non-infected household members was significantly higher than that of infected members (median 7000 vs. 4000, p=0.005). This persisted when adjusting median antibody titer for age (univariate OR 0.96, 95% CI 0.93-0.99, p=0.005; multivariate OR 0.96, 95% CI 0.93-0.99, p=0.003; Table IV). 3.4. Sequencing and phylogenetic results Sequence analysis was successful for 115 SARS-CoV-2 positive individuals originating from 62 households, of whom 59 indexes and 56 household members. For 27 of 40 (67.5%) households with transmission or positive household member(s), sequences were available for both the index and all positive members. For four households, sequences were available for the index and one positive household member. The phylogeny of these sequences showed a distinct cluster with minimal sequence differences in 23 of the 27 (85.2%) households with fully known sequences and in all four incomplete households, indicative of a single introduction within each household (Figure II). However, in four households, sequences showed large genetic distances between each of the household members or their appointed index case, indicating multiple, independent introductions of SARS-CoV-2 into the household. The subsequent sensitivity analysis took these cases into account.

3.5. Recent positive household members (RPHMs) and sequencing

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

Sequencing was performed on available isolates of RPHMs who tested positive within two weeks before inclusion to investigate whether these cases were related to the later transmission within the household. Of the six RPHMs that tested positive within two weeks before inclusion, four sequences became available. Three of these isolates showed clustering with other members of the household, including the index case, indicative of mutual transmission. One sequence was not closely related to other members, showing an independent introduction. Therefore, the three RPHMs with confirmed similar sequences could be appointed as the actual index case. Moreover, the two RPHMs with unknown sequences could not be excluded as the actual index. The subsequent sensitivity analysis corrected for these five cases. 3.6. Sensitivity analysis The selection of households and household members for sensitivity analysis to calculate the minimal household and per-person SAR is visualized in Supplementary Figure I and II. First, the sensitivity analysis excluded the above-mentioned five households containing five indexes and their 13 household members with a possible other primary case (RPHM) than the defined index. Moreover, for the calculation of the minimal household SAR, 11 additional households were excluded because transmission from the index to at least one household member could not be confirmed by sequencing (Figure II) or sequencing showed more than one introduction into the household. Transmission was confirmed by phylogenetic analysis in 26 of 51 remaining households, resulting in a minimal household SAR of 51.0%. Thereby, the household SAR estimates changed from the crude estimation (maximal household SAR) of 59.7% to the corrected sensitivity estimation (minimal household SAR) of 51.0%. Similarly, for the calculation of the minimal per person SAR, SARS-CoV-2 positive household members were excluded if transmission from the index to this household member was not confirmed by sequencing, leading to the exclusion of 28 positive household members. Transmission from index to household member was proven by sequencing in 37 of 71 positive household members (52.1%). Since 93 negative household members were remaining, the corrected minimal per person SAR is 28.5% (37/130). Thereby, the household member SAR estimates changed from the crude estimation (maximal per-person SAR) of 41.5% to the corrected sensitivity estimation (minimal per-person SAR) of 28.5%. The characteristics of households, index cases and household members included in the sensitivity analysis are presented in Supplementary Table I-III. Characteristics associated with transmission were not different between the primary and sensitivity analysis (Supplementary Tables I–III).

4. Discussion

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

This study prospectively analysed household transmission of the SARS-CoV-2 Omicron BA.2 VOC using dense saliva sampling and phylogenetic analysis and compared results with pre-immunisation household transmission rates of the ancestral variant, using a largely identical study design. Despite the finding that infection-acquired immunity, hybrid immunity and higher baseline antibody titer of household members significantly decreased infection risk, this study still found high transmission rates: household SAR 51.0%-59.7% and per-person SAR 28.5%-41.5%. Here, we showed a decrease of 10 percentage points for the household SAR and 14 percentage points for per-person SAR when correcting for our index case definition and infections from outside the household. The multiple simultaneous introductions detected within households emphasise the relevance of phylogenetic analysis to validate transmission within each household. This study also reveals that transmission occurs within a short time interval after infection of the index case. Moreover, underage index cases were more likely to transmit the virus to household members compared to adult indexes. This study found high SARs, which fall within the broad range of household SARs reported in other Omicron household transmission studies, varying between 15.0%-70.2%. 8,10,22 This wide range of reported transmission rates, partially caused by variability in study methods, has been found in all pandemic phases, comprising diverse SARS-CoV-2 variants and immune statuses. This makes comparison of SARs between pandemic phases challenging. However, comparing transmission rates is necessary to specify the net impact of the highly transmissible Omicron variant versus immunity on transmission. These challenges were overcome by comparing two studies with almost identical designs, thereby distilling the net impact. In our previous identical study performed in December 2020-January 2021, we reported household SAR of 88.2% and per-person SAR of 64.3%. The Omicron BA.2 household transmission rates observed in the current study were clearly lower compared to that observed in the initial early-pandemic study of ancestral SARS-CoV-2 in an immune naïve population:9 the household SAR estimates decreased from 88.2% to 59.7%, and the per-person SAR reduced from 64.3% to 41.5% compared to the initial estimates at the start of the pandemic. This remarkable decrease in household transmission rate of the Omicron VOC in a high-immunised cohort, despite the higher transmissibility phenotype of Omicron, emphasises the relevance of immunity to hamper transmission. In the current study, higher baseline antibody titer in household members was associated with protection against transmission. Thereby, participant-reported infection-induced and hybrid immunity of household members are both associated with protection against Omicron VOC household transmission, as shown in the current study and a previous household study. 10 The vaccine effectiveness against household transmission in absence of prior infection is less

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

prominent in this study, possibly related to the fact that vaccines contained the ancestral strain at the time or the limited size of our study population. However, various studies indicate that indexes with prior immunity acquired by vaccination reduce Omicron household transmission compared to non-vaccinated indexes. 15,17,23,24 although vaccine effectiveness is lower for the Omicron variant than for previous variants.²⁵ Thus, pre-existing immunity has a reductive impact on household transmission, although new variants challenge this by immune escaping strategies. These strategies oppose a steep reduction in transmission rate, which still allows the virus to spread substantially. This study found that children were more likely to transmit the Omicron BA.2 variant to household members, and that children were as susceptible to infection with this variant as adult household members. However, our previous study did not find children to have a pivotal role in the household transmission of SARS-CoV-2.9 This shift is in line with literature, showing an increased role of children in household transmission since the emergence of VOCs compared to the first pandemic phase.²⁶ One cause of increased transmission from children to their household members relative to the ancestral virus could be the different immunisation rates between children and adults, since immunisation is shown to play a role in preventing SARS-CoV-2 household transmission in this and other studies. ^{15,17,24,25} However, this study observed that children still have a significantly increased risk of transmitting SARS-CoV-2 after adjusting for immunisation status. This may be because young children are more likely to spend time with family compared to other age groups. However, it also supports the hypothesis that the evolution of the virus over time resulted in an increased role for children in transmission over the course of the pandemic.²⁶ This could be attributed to the finding that the ancestral strain, but not the Omicron variant, is less efficient at replicating in the primary nasal epithelial cells of children, which may impact the viral shedding of children compared to adults. 27 This study detected multiple introductions in at least four households by whole genome sequencing. In times of high incidence and regular social interaction patterns, it is possible that household members independently become infected by different sources. These introductions from external sources into the household may result in an overestimation of the household transmission rate if left undetected. In the initial early-pandemic study, performed in a lockdown period with strict preventative measures such as the closure of public locations and schools, sequencing and phylogenetic results showed no evidence of multiple introductions within households. To our knowledge, this is the first household transmission study performing whole genome sequencing in both indexes and household members during the Omicron wave, describing multiple introductions within one

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

household and performing a sensitivity analysis to calculate corrected (minimal) transmission rates. Thereby, the reported transmission estimates in this study more accurately approach the true rates. There are some limitations. First, a selection bias is introduced towards symptomatic index cases since symptomatic individuals are more likely to test themselves, while many asymptomatic cases are easily overlooked.²⁸ Not only does this affect the entire pool enrolled in this study, but this might also affect the appointment of the index within households towards a symptomatic member. Although overlooking an asymptomatic index case cannot be prevented entirely, testing history and symptoms up to 8 weeks before inclusion were investigated. Second, as no lockdown measures were implemented in the Netherlands at the time of this study, and many of the participants were positive at study start, the possibility of an external case that infected all household members at once cannot be excluded. Third, recruiting after voluntary testing at facilities may introduce a volunteer bias towards those who are more inclined to adhere to COVID-19 testing measures and isolation policies.²⁹ This could potentially result in higher transmission rates in the general population. In conclusion, by using dense saliva sampling and phylogenetic analysis, this study reveals that the household transmission of the Omicron BA.2 VOC is high despite immunization. However, the transmission rate is lower compared to previous studies with other SARS-CoV-2 variants, highlighting the effect of immunity. Children have a crucial role in household transmission, while immunity has been demonstrated to provide protection against household member infection. Moreover, this study found multiple unique introductions in households by whole genome sequencing, which emphasises the importance of sequencing in future household transmission studies. These findings thereby contribute to the design of future transmission studies and the development of future public health strategies.

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

Authors' contributions SvL, DE, MAvH, JSP, AW, MH, CR contributed to the conception and design of the study; AW, SvL, MEH, participated in the acquisition of data; DE and EK coordinated the laboratory analyses; AW, EK, SvL, JGCS, SE, DE, and MAvH were responsible for data analyses and interpretation; AW, EK, SE, SvL and DE verified the underlying data; AW, EK, SvL, DE wrote the manuscript. All authors had full access to all the data and reviewed and approved the final version of the manuscript. Corresponding authors SFL van Lelyveld, E-mail: s.van.lelyveld@spaarnegasthuis.nl; D Eggink, E-mail: dirk.eggink@rivm.nl. **Declaration of interests** We declare no competing interests. Data availability statement Deidentified data collected for the study, including individual participant data collected during the study and a data dictionary, will be shared upon reasonable request. These requests will be discussed with all project partners (Spaarne Gasthuis and RIVM). Requests should be directed to s.van.lelyveld@spaarnegasthuis.nl or dirk.eggink@rivm.nl. These requests will be reviewed and approved by the investigator and project partners based on scientific merit. To gain access, data requesters will need to sign a data access agreement. Privacysensitive data, which is traceable to the participant, will not be shared. Acknowledgements, funding and meeting(s) where the information has previously been presented There were no funding sources. The data has not been presented in international meetings. We thank the team of the Public Health Services (GGD) Kennemerland for providing information to the (possible) participants, the laboratory team of the National Institute for Public Health and the Environment (RIVM), including Sophie van Tol, Gert-Jan Godeke, Coralie Valle, Lisa Wijsman, Bas van der Veer, Annemarie van den Brandt, Jeroen Cremer, Sharon van den Brink, Ryanne Jaarsma, Kim Freriks, Lynn Aarts, Sanne Bos, Mansoer Elahi, Jil Kocken for the laboratory analyses and the research team of the Spaarne Gasthuis Academy, particularly Jacqueline Zonneveld, Sandra Kaamer van Hoegee, Mara van Roermund, Josseline Veldhuijzen and Yara Sijm for their hard work and efforts concerning the continuation of the SARSLIVA 2.0 study.

360 361 362 References 363 1. (WHO) World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Vol. 2023. [cited 2023 364 Jun 27]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants 365 2. Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran T Bin, Wilairatana P. Omicron variant 366 (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of 367 SARS-CoV-2? Biomed Pharmacother. 2022;154:113522. 368 3. National Institute for Public Health and the Environment (RIVM). Variants of the coronavirus SARS-369 CoV-2 [Internet]. [cited 2023 Jun 28]. Available from: https://www.rivm.nl/en/coronavirus-covid-370 19/virus/variants 371 4. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron 372 variants BA.1 to BA.5: Implications for immune escape and transmission. Rev Med Virol. 373 2022;32(5):e2381. 374 5. Dejnirattisai W, Huo J, Zhou D, Schreiber G, Stuart DI, Screaton GR, et al. SARS-CoV-2 Omicron-375 B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467–84. 376 6. Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al. Breakthrough 377 infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 378 2022;399(10325):625–6. 379 7. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics, and 380 controllability of SARS-CoV-2. Science (1979). 2021;371(6526). 381 8. Madewell ZJ, Yang Y, Jr IML, Halloran ME, Dean NE. Household Secondary Attack Rates of SARS-382 CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis. JAMA 383 Netw Open. 2022;5(4):e229317. 384 9. Kolodziej LM, van Lelyveld SFL, Haverkort ME, Mariman R, Sluiter-Post JGC, Badoux P, et al. High 385 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission Rates 386 Detected by Dense Saliva Sampling. Clin Infect Dis. 2022;75(1):e10–9.

- 387 10. Frutos AM, Kuan G, Lopez R, Ojeda S, Shotwell A, Sanchez N, et al. Infection-induced immunity is 388 associated with protection against SARS-CoV-2 infection and decreased infectivity. Clin Infect Dis. 389 2023;76(12):2126-33. 390 11. Reukers DFM, van Boven M, Meijer A, Rots N, Reuken C, Roof I, et al. High Infection Secondary 391 Attack Rates of Severe Acute Respiratory Syndrome Coronavirus 2 in Dutch Households Revealed by 392 Dense Sampling. Clin Infect Dis. 2022 Jan;74(1):52–8. 393 12. National Institute for Public Health and the Environment (RIVM). Archive COVID-19 vaccination 394 figures 2022 [Internet]. Vol. 2023. [cited 2023 Jun 27]. Available from: https://www.rivm.nl/en/covid-395 19-vaccination/archive-covid-19-vaccination-figures-2022 396 13. National Institute for Public Health and the Environment (RIVM). Results Pienter Corona-Study Round 397 7 [Internet]. Vol. 2023. [cited 2023 Jun 27]. Available from: https://www.rivm.nl/pienter-corona-398 onderzoek/resultaten/ronde-7 399 14. Baker JM, Nakayama JY, O'Hegarty M, McGowan A, Teran RA, Bart SM, et al. SARS-CoV-2 400 B.1.1.529 (Omicron) Variant Transmission Within Households - Four U.S. Jurisdictions, November 401 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(9):341-6. 402 15. Lee J, Ko M, Kim S, Lim D, Park G, Lee SE. Household secondary attack rates and risk factors during 403 periods of SARS-CoV-2 Delta and Omicron variant predominance in the Republic of Korea. Osong 404 Public Health Res Perspect. 2023;14(4):263-71. 405 16. Lyngse FP, Mølbak K, Denwood M, Christiansen LE, Møller CH, Rasmussen M, et al. Effect of 406 vaccination on household transmission of SARS-CoV-2 Delta variant of concern. Nat Commun. 2022 407 Jun;13(1):3764-y. 408 17. Jalali N, Brustad HK, Frigessi A, Macdonald EA, Meijerink H, Feruglio SL, et al. Increased household 409 transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants. Nat 410 Commun. 2022;13(1):5706.
- Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T, Aginagalde Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-
- 413 CoV-2 Omicron Variant, Spain. Emerg Infect Dis. 2022;28(6):1224–8.

- 414 19. Veneti L, Bøås H, Kristoffersen AB, Stålcrantz J, Bragstad K, Hungnes O, et al. Reduced risk of
- 415 hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant
- 416 compared with the Delta variant, Norway, December 2021 to January 2022. Euro Surveill.
- 417 2022;27(4):2200077.
- 418 20. Stanoeva KR, van der Eijk AA, Meijer A, Kortbeek LM, Koopmans MPG, Reusken CBEM. Towards a
- 419 sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264
- 420 studies. Euro Surveill. 2021;26(10):2001134.
- 421 21. Artic Network. Protocols [Internet]. [cited 2022 Aug 22]. Available from: https://artic.network/2-
- 422 protocols.html
- 423 22. Allen H, Tessier E, Turner C, Anderson C, Blomquist P, Simons D, et al. Comparative transmission of
- 424 SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination:
- national cohort study, England. Epidemiol Infect. 2023;151:e58.
- 426 23. Ogata T, Tanaka H, Tanaka E, Osaki N, Noguchi E, Osaki Y, et al. Increased Secondary Attack Rates
- 427 among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in
- 428 Japan. J Environ Res Public Health. 2022;19(13):8068.
- 429 24. Kim YC, Kim B, Son NH, Heo N, Nam Y, Shin A, et al. Vaccine Effect on Household Transmission of
- Omicron and Delta SARS-CoV-2 Variants. J Korean Med Sci. 2023;38(1):e9.
- 431 25. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2
- 432 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200.
- 433 26. Zhu Y, Xia Y, Pickering J, Bowen AC, Short KR. The role of children in transmission of SARS-CoV-2
- 434 variants of concern within households: an updated systematic review and meta-analysis, as at 30 June
- 435 2022. Euro Surveill. 2023;28(18):2200624.
- 436 27. Id YZ, Chew KY, Wu M, Karawita AC, Mccallum G, Steele LE, et al. Ancestral SARS-CoV-2, but not
- 437 Omicron, replicates less efficiently in primary pediatric nasal epithelial cells. 2022 [cited 2024 Mar 1];
- 438 Available from: https://doi.org/10.1371/journal.pbio.3001728
- 439 28. Suhail Y, Afzal J, Kshitiz. Incorporating and addressing testing bias within estimates of epidemic
- dynamics for SARS-CoV-2. BMC Med Res Methodol. 2021;21(1):11.

29. Kennedy EB, Charifson M, Jehn M, Jensen EA, Vikse J. Prospective sampling bias in COVID-19 recruitment methods: experimental evidence from a national randomized survey testing recruitment materials. BMC Med Res Methodol. 2022;22(1):251.
30. Centers for Disease Control Prevention (CDC). Z-score Data Files [Internet]. Available from: https://www.cdc.gov/growthcharts/zscore.htm

	Total no of participants	Index cases	Household members		
N	241	70	171		
Characteristic				P ^a	OR ^b [95% CI]
Child (<18 y)	100 (41.5)	24 (34.3)	76 (44.4)	0.147	0.65 [0.37-1.16]
Adult	141 (58.5)	46 (65.7)	95 (55.6)	0.147	1.53 [0.86-2.73]
Age, y, median (IQR)	33.0 (12.0-46.0)	38.0 (11.8-48.3)	21.0 (12.0-45.0)	0.058	1.02 [0.99-1.03]
Age group, y					
< 12	57 (23.7)	17 (24.3)	40 (23.4)		1 (ref)
12-17	43 (17.8)	7 (10.0)	36 (21.1)	0.121	0.46 [0.17-1.23]
18-39	43 (17.8)	13 (18.6)	30 (17.5)	0.965	1.02 [0.43-2.42]
40-49	69 (28.6)	21 (30.6)	48 (28.1)	0.941	1.03 [0.48-2.21]
50-65	29 (12.0)	12 (17.1)	17 (9.9)	0.286	1.66 [0.65-4.22]
Sex, female	123 (51.0)	43 (61.4)	80 (46.8)	0.040*	1.81 [1.03-3.20]
BMI class ^c					
Normal weight	162 (67.2)	47 (67.1)	115 (67.3)		1 (ref)
Overweight	43 (17.8)	8 (11.4)	35 (20.5)	0.175	0.56 [0.24-1.30]
Obesity	23 (9.5)	11 (15.7)	12 (7.0)	0.074	2.24 [0.93-5.44]
Underweight	13 (5.4)	4 (5.7)	9 (5.3)	0.893	1.09 [0.32-3.71]
Atopic constitution	82 (34.0)	24 (34.3)	58 (33.9)	0.956	1.02 [0.57-1.83]
Underlying medical condition ^d	33 (13.7)	9 (12.9)	24 (14.0)	0.809	0.90 [0.40-2.06]
Cardiovascular disease	6 (2.5)	2 (2.9)	4 (2.3)	0.815	1.23 [0.22-6.86]
Immune disorder	4 (1.7)	1 (1.4)	3 (1.8)	0.858	0.81 [0.08-7.94]
Diabetes	4 (1.7)	1 (1.4)	3 (1.8)	0.858	0.81 [0.08-7.94]
Lung disease	1 (0.4)	1 (1.4)	0		
Other	18 (7.5)	4 (5.7)	14 (8.2)	0.605	0.74 [0.23-2.34]
Pre-existing immunity					
Naïve	26 (10.8)	8 (11.4)	18 (10.5)		1 (ref)
Previous infection only ^e	30 (12.4)	8 (11.4)	22 (12.9)	0.735	0.82 [0.26-2.61]
Previous vaccination only ^f	127 (52.7)	43 (61.4)	84 (49.1)	0.761	1.15 [0.46-2.86]
Hybrid ^g	58 (24.1)	11 (15.7)	47 (27.5)	0.236	0.53 [0.18-1.52]
Vaccination-status 5-11 years		, ,			
Unvaccinated	39 (86.7)	13 (81.3)	26 (89.7)		1 (ref)
1x	5 (11.1)	3 (18.8)	2 (6.9)	0.259	3.00 [0.45-20.24]
2x	1 (2.2)	0	1 (3.4)	1.000	
Vaccination status ≥ 12 years					
Unvaccinated	5 (2.7)	2 (3.8)	3 (2.3)		1 (ref)
1x	3 (1.6)	1 (1.9)	2 (1.5)	0.851	0.75 [0.04-14.97]
2x	78 (42.4)	15 (28.3)	63 (48.1)	0.282	0.36 [0.06-2.33]
3x/booster vaccinated	98 (53.3)	35 (66.0)	63 (48.1)	0.846	0.83 [0.13-5.23]
Antibody titer day 1, median	,0 (55.5)	22 (30.0)	00 (10.1)	0.010	0.00 [0.10 0.20]

Abbreviations: BMI, body mass index; CI, confidence interval; IQR, interquartile range; OR, odds ratio; y, year.

^a P-value for comparison between household members and index cases.

^bOdds Ratio for comparison between household members and index cases.

^c BMI categories for index cases and household members <18 years of age were defined as BMI z-score <-2, underweight; −2 to 1, normal weight; 1−2, overweight; >2, obesity. ³⁰ BMI categories for index cases and household members ≥18 years of age were defined as <18.5 kg/m2, underweight; 18.5–24.9 kg/m2, normal weight; 25.0–29.9 kg/m2, overweight; ≥30.0 kg/m2, obesity.

- ^d Cardiovascular disease, lung disease, immune disorder, diabetes and other disorders.
- ^e Only previous infection

- f Only previous vaccination
- ^g Previous infection and vaccination (at least one vaccination) (hybrid immunity)
- ^h Blood available for 66 index cases (66/70, 94.3%) and 152 household members (152/171, 88.9%).

Table II - Household characteristics (N=67)						
	Total households	Households with secondary transmission	Households without secondary transmission		Household secondary attack rate (%)	
N	67	40	27		59.7	
Characteristic				$\mathbf{P}^{\mathbf{a}}$	OR ^b [95%CI]	
Median household size (IQR)	4.0 (4.0-4.0)	4.0 (4.0-4.0)	4.0 (4.0-4.0)	0.798	1.12 [0.47-2.66]	
Household size, No. of persons						
3	14 (20.9)	8 (20.0)	6 (22.2)		1 (ref)	
4	45 (67.2)	27 (67.5)	18 (66.7)	0.849	1.13 [0.33-3.79]	
5	8 (11.9)	5 (12.5)	3 (11.1)	0.806	1.25 [0.21-7.41]	

The household secondary attack rate was 59.7%.

450

451

Abbreviations: CI, confidence interval; IQR, interquartile range; OR, odds ratio.

^a P-value for comparison between households with secondary transmission and households without secondary transmission.

^b Odds Ratio for comparison between households with secondary transmission and households without secondary transmission.

	Total index cases	Index cases of households with transmission	Index cases of households without transmission		
N	70	42	28		
				Univaria	te logistic regression
Characteristic				$\mathbf{P}^{\mathbf{a}}$	OR [95% CI]
Child (<18 y)	24 (34.3)	20 (47.6)	4 (14.3)	0.006*	5.46 [1.61-18.47]
Adult	46 (65.7)	22 (52.4)	24 (85.7)	0.006*	0.18 [0.05-0.62]
Age, y, median (IQR)	38.0 [11.8-48.3]	18.5 [8.8-43.0]	46.5 [41.0-50.8]	<0.001*	0.94 [0.91-0.98]
Age group, y					
< 12	17 (24.3)	15 (35.7)	2 (7.1)	0.002*	22.50 [3.14-161.47]
12-17	7 (10.0)	5 (11.9)	2 (7.1)	0.060	7.50 [0.92-61.05]
18-39	13 (18.6)	11 (26.2)	2 (7.1)	0.006*	16.50 [2.25-121.23]
40-49	21 (30.6)	8 (19.0)	13 (46.4)	0.446	1.85 [0.38-8.93]
50-65	12 (17.1)	3 (7.1)	9 (32.1)		1 (ref)
Sex, female	43 (61.4)	27 (64.3)	16 (57.1)	0.548	1.35 [0.51-3.59]
BMI class ^c					
Normal weight	47 (67.1)	31 (73.8)	16 (57.1)		1 (ref)
Overweight	8 (11.4)	2 (4.8)	6 (21.4)	0.044*	1.17 [0.03-0.95]
Obesity	11 (15.7)	5 (11.9)	6 (21.4)	0.214	0.43 [0.11-1.63]
Underweight	4 (5.7)	4 (9.5)	0	••	
Atopic constitution	24 (34.3)	16 (38.1)	8 (28.6)	0.412	1.54 [0.45-4.31]
Underlying medical condition ^d	9 (12.9)	6 (14.3)	3 (10.7)	0.663	1.39 [0.32-6.08]
Pre-existing immunity					
Naïve or unknown infection	8 (11.4)	7 (16.7)	1 (3.6)		1 (ref)
Previous infection only ^e	8 (11.4)	6 (14.3)	2 (7.1)	0.529	0.43 [0.03-5.99]
Previous vaccination only ^f	43 (61.4)	24 (57.1)	19 (67.9)	0.124	0.18 [0.02-1.60]
Hybrid ^g	11 (15.7)	5 (11.9)	6 (21.4)	0.083	0.12 [0.01-1.32]
Time interval till study onset in weeks, median (IQR)					
Last infection ^e	16.1 (12.5-19.8)	16.6 (15.0-30.0)	10.4 (8.4-)	0.977	
Last vaccination ^f	11.9 (10.0-15.9)	11.7 (10.1-16.6)	12.6 (9.9-15.7)	0.624	1.02 [0.94-1.10]
Last infection or vaccination ^g	13.3 (8.7-14.6)	13.7 (5.8-32.9)	11.8 (6.6-13.8)	0.359	1.01 [0.93-1.24]
Antibody titer day 1h					
≤10	4 (5.7)	3 (7.1)	1 (3.6)		1 (ref)
10-100	1 (1.4)	1 (2.4)	0		
>10	62 (88.6)	36 (85.7)	26 (92.9)	0.513	0.46 [0.05-4.69]
>100	61 (87.1)	35 (83.3)	26 (92.9)	0.498	0.50 [0.04-4.56]
>1000	55 (78.6)	29 (69.0)	26 (92.9)	0.404	0.37 [0.04-3.80]
>3000	40 (57.1)	20 (47.6)	20 (71.4)	0.359	0.33 [0.03-3.48]
>10.000	18 (25.7)	6 (14.3)	12 (42.9)	0.154	0.17 [0.01-1.96]
N.A.	4 (5.7)	3 (7.1)	1 (3.6)	1.000	1.00 [0.04-24.55]
Antibody titer day 1, median (IQR) ^h	5000 (1000-11250)	3000 (1000-7000)	9000 (3000-15000)	0.049*	0.95 [0.90-1.00]
Symptom status ⁱ					
Severe symptoms ^j	0	0	0	••	
Moderate symptoms	19 (27.1)	13 (31.0)	6 (21.4)	0.335	2.17 [0.45-10.44]
Mild symptoms	41 (58.6)	24 (57.1)	17 (60.7)	0.626	1.41 [0.35-5.65]
Asymptomatic	10 (14.3)	5 (11.9)	5 (17.9)		1 (ref)
Days of symptoms before study onset (day 1), median (IQR)	3.0 (2.0-4.0) (N=56)	3.0 (2.0-4.0) (N=36)	2.5 (2.0-3.8)	0.402	1.17 [0.81-1.70]

Abbreviations: BMI, body mass index; CI, confidence interval; IQR, interquartile range; OR, odds ratio; SD, standard deviation; y, year.

- ^a P-value for comparison between index cases in households with secondary transmission and households without secondary transmission.
- ^b Odds Ratio for comparison between index cases in households with secondary transmission and households without secondary transmission.
- ^c BMI categories for index cases and household members <18 years of age were defined as BMI z-score <-2, underweight; −2 to 1, normal weight; 1–2, overweight; >2, obesity.³⁰ BMI categories for index cases and household members ≥18 years of age were defined as <18.5 kg/m2, underweight; 18.5–24.9 kg/m2, normal weight; 25.0–29.9 kg/m2, overweight; ≥30.0 kg/m2, obesity.
- ^d Cardiovascular disease, lung disease, immune disorder, diabetes, rheumatic disorder, and other disorders.
- e Index cases with previous infection only (n=8)
- f Index cases with previous vaccination only (n=43)
- g Index cases with previous infection and vaccination (at least one vaccination) (hybrid immunity) (n=11)
- ^h Blood available for 66 index cases (66/70, 94.3%).
- ¹Maximum over ten time points.

452

j Hospital admission due to coronavirus-related symptoms.

	Total number of household members at risk	Secondary case	No secondary case		Per person secondary attack rate (%)
N	171	71	100		58.5
				Univ	ariate logistic regression
Characteristic				$\mathbf{P}^{\mathbf{a}}$	OR ^b [95CI]
Child (<18 y)	76 (44.4)	31 (43.7)	45 (45.0)	0.862	0.95 [0.51-1.75]
Adult	95 (55.6	40 (56.3)	55 (55.0)	0.862	1.06 [0.57-1.95]
Age, y, median (IQR)	21.0 (12.0-45.0)	36.0 [10.0-46.0]	20.0 [12.0-45.0]	0.620	1.00 [0.99-1.02]
Age group, y					
< 12	40 (23.4)	21 (29.6)	19 (19.0)	0.976	0.98 [0.32-3.06]
12-17	36 (21.1)	10 (14.1)	26 (26.0)	0.079	0.34 [0.10-1.14]
18-39	30 (17.5)	11 (15.5)	19 (19.0)	0.281	0.52 [0.15-1.72]
40-49	48 (28.1)	20 (28.2)	28 (28.0)	0.423	0.64 [0.21-1.93]
50-65	17 (9.9)	9 (12.7)	8 (8.0)		1 (ref)
Sex, female	80 (46.8)	37 (52.1)	43 (43.0)	0.240	1.44 [0.78-2.66]
BMI class ^c					
Normal weight	115 (67.3)	42 (59.2)	73 (73.0)		1 (ref)
Overweight	35 (20.5)	17 (23.9)	18 (18.0)	0.203	1.64 [0.77-3.52]
Obesity	12 (7.0)	6 (8.5)	6 (6.0)	0.364	1.74 [0.53-5.73]
Underweight	9 (5.3)	6 (8.5)	3 (3.0)	0.089	3.48 [0.83-14.63]
Atopic constitution	58 (33.9)	25 (35.2)	33 (33.0)	0.763	1.10 [0.58-2.10]
Underlying medical condition ^d	24 (14.0)	11 (15.5)	13 (13.0)	0.644	1.23 [0.52-2.92]
Pre-existing immunity					
Naïve or unknown infection	18 (10.5)	14 (19.7)	4 (4.0)		1 (ref)
Previous infection only ^e	22 (12.9)	7 (9.9)	15 (15.0)	0.006*	0.13 [0.03-0.56]
Previous vaccination only ^f	84 (49.1)	44 (62.0)	40 (40.0)	0.057	0.31 [0.10-1.03]
Hybrid ^g	47 (27.5)	6 (8.5)	41 (41.0)	<0.001*	0.04 [0.01-0.17]
Time interval till study onset in weeks, median (IQR)					
Last infection ^e	15.8 (12.4-20.7)	15.4 (13.3-15.9)	16.7 (10.6-39.4)	0.279	0.94 [0.85-1.05]
Last vaccination ^f	12.7 (10.1-16.6)	11.8 (10.1-16.4)	13.3 (9.9-16.8)	0.778	0.99 [0.94-1.05]
Last infection or vaccination ^g	10.7 (8.7-16.1)	18.5 (8.5-22.7)	10.4 (8.6-14.6)	0.047*	1.15 [1.00-1.33]
Antibody titer day 1 ^h					
≤10	8 (4.7)	6 (8.5)	2 (2.0)	0.55.	1 (ref)
10-100	3 (1.8)	1 (1.4)	2 (2.0)	0.224	0.17 [0.01-2.98]
>10	144 (84.2)	55 (77.5)	89 (89.0)	0.058	0.21 [0.04-1.06]
>100	141 (82.5)	54 (76.1)	87 (87.0)	0.059	0.21 [0.04-1.06]
>1000	125 (73.1)	47 (66.2)	78(78.0)	0.055	0.20 [0.04-1.04]
>3000	99 (57.9)	36 (50.7)	63 (63.0)	0.049*	0.19 [0.04-0.99]
>10.000	55 (32.2)	14 (25.5)	41 (41.0)	0.013*	0.11 [0.02-0.63]
N.A. Antibody titer day 1, median (IQR) ^h	19 (11.1) 5500 (2000-16000)	10 (14.1) 4000 (1500-10000)	9 (9.0) 7000 (2000-21000)	0.289 0.005*	0.37 [0.06-2.32] 0.96 [0.93-0.99]
Symptom status ⁱ					
Severe symptoms ^j	<u>-</u>	<u>-</u>	-		
Moderate symptoms	32 (18.7)	19 (26.8)	13 (13.0)	<0.001*	12.57 [3.92-40.26]
Mild symptoms	91 (53.2)	47 (66.2)	44 (44.0)	<0.001*	9.19 [3.34-25.30]
Asymptomatic	48 (28.1)	5 (7.0)	43 (43.0)	.5.001	1 (ref)


Abbreviations: BMI, body mass index; CI, confidence interval; IQR, interquartile range; OR, odds ratio; y, year

- ^a P-value for comparison between SARS-CoV-2 positive household members and SARS-CoV-2 negative household members
- ^b Odds Ratio for comparison between SARS-CoV-2 positive household members and SARS-CoV-2 negative household members
- ^c BMI categories for index cases and household members <18 years of age were defined as BMI z-score <−2, underweight; −2 to 1, normal weight; 1−2, overweight; >2, obesity. BMI categories for index cases and household members ≥18 years of age were defined as <18.5 kg/m2, underweight; 18.5–24.9 kg/m2, normal weight; 25.0–29.9 kg/m2, overweight; ≥30.0 kg/m2, obesity.
- ^d Cardiovascular disease, lung disease, immune disorder, diabetes, rheumatic disorder, and other disorders.
- ^e Household members with previous infection only (n=22)
- Household members with previous vaccination only (n=84)
- g Household members with previous infection and vaccination (at least 1 vaccination) (hybrid immunity) (n=47)
- ^h Blood available for 152 household members (152/171, 88.9%).
- Maximum over ten time points.

453

^j Hospital admission due to coronavirus-related symptoms.

Figure I. Study design




Households consisting of index case(s) and at least two household members were enrolled upon a PCR–confirmed index case. SARS-CoV-2 PCR was performed on saliva samples obtained on days 1, 3, 5, 7, 10, 14, 21, 28, 35, and 42. Whole genome sequencing was performed on the saliva samples with the highest viral load for phylogenetic analysis. SARS-CoV-2 antibodies were measured in serum samples collected on days 1 and 42. Symptom questionnaires were obtained on saliva sampling days. Household members with a confirmed SARS-CoV-2 infection within eight weeks before study-onset (RPHM) were not eligible to participate fully in the study as RNA detection from the earlier infection might affect transmission data. Their recent positive NP/OP-sample was sequenced and compared with index case and household members to investigate a possible role of this participant in SARS-CoV-2 transmission within the household.

Abbreviations: Max, maximum; PCR, polymerase chain reaction.

Figure created in BioRender.com

Figure II. Phylogenetic analysis of SARS-CoV-2 sequences within households

Household Phylogeny



Maximum likelihood phylogenetic tree based on all sequences obtained from (each SARS-CoV-2 positive) participants' saliva samples with the highest viral load. The tree shows the genetic distance between sequences, to check for single or multiple introductions of the virus within one household. Sequences of index and household members are coloured per household. Therefore, the different colours each represent a household. Households are numbered H01 to H59. Each dot represents the sequence of the specimen of one of the participants. This figure only shows the sequences of those households for which whole genome sequencing succeeded for multiple sequences of which at least one household member (in 85 individuals of 32 households). Sequences that cluster, are displayed in close proximity in this tree, suggesting infection with the same strain, which is expected in case of actual transmission. Asterisks indicate the households with genetically diverse

sequences between its' household members and/or index case. Genetically diverse sequences between the members of a household shows that this household had multiple introductions of the virus, instead of spread from one index case to other members of the household. These households with genetically diverse sequences are removed for our sensitivity analyses. Therefore, only households where transmission from index case to its' household members was confirmed by sequencing are included in the sensitivity analysis. In this sensitivity analysis, a minimal SAR was calculated of only proven transmission.

455